The emerging growth of lipophilic active ingredients, and the lack of suitable knowhow on improved drug delivery systems for lipophilic compounds, cause a void between drug discovery and final ready-to-market pharmaceutical products. Our highly advanced Drug Delivery Technology (DDT) Alitra™ offers a practical solution for administering lipophilic compounds in patients. Reduced use of surfactant is an additional advantage of Alitra™, as the emulsifying technology is capable of formulating API’s with an improved solubility.
Alitra™ distinguishes itself by significantly improving the absorption of poor water soluble compounds in the human blood, presenting a favorable bioavailability and demonstrating steadier temporal profiles. Alitra™ has proven to be especially useful for drugs for which low water-solubility and deterioration in the gastrointestinal system contribute to a low oral bioavailability.